
Mazdutide
Mazdutide is a once-weekly injection that acts on the GLP-1 and glucagon receptors. It is approved in China for weight management and type 2 diabetes but not in the US. In Chinese phase 3 trials, adults lost an average of 11.0% to 14.0% of body weight over 48 weeks on 4 mg or 6 mg, and 16.65% over 60 weeks on 9 mg, compared with almost no change on placebo. In a US phase 2 trial, higher doses up to 16 mg produced more weight loss but more people stopped because of side effects.
Prescription medication: not a dietary supplement
This is an FDA-approved (or investigational) drug, not a supplement. It requires a prescription and medical supervision. The information below summarizes clinical-trial evidence for education only. It is not a recommendation to obtain or use it without a doctor.
Quick decision guide
May help most
In the US, adults with obesity or type 2 diabetes who qualify for and choose to join a registered clinical trial; everyone else can ask a doctor about approved options
Common dosing range
No FDA-approved dose. Chinese phase 3 trials studied 4 mg, 6 mg or 9 mg once weekly; a US phase 2 trial studied 3 to 16 mg
When to expect effects
Weight loss measured at 24 to 60 weeks; blood sugar at 24 to 28 weeks
Watch out for
Not FDA-approved and cannot be prescribed in the US outside a trial; FDA has warned sellers of unapproved "research" mazdutide. Vomiting and nausea were very common in the 9 mg trial, and the published phase 3 trials enrolled only Chinese adults
What is it
Mazdutide is an investigational drug in the United States: it is not FDA-approved for any use, so it cannot be prescribed in the US outside a clinical trial, and any product sold in the US as mazdutide (including vials labeled "for research use only") is unapproved and unverified. FDA has warned companies that illegally sold unapproved drugs containing mazdutide falsely labeled "for research purposes" or "not for human consumption" for human use. Outside the US, China approved mazdutide in June 2025 for long-term weight management, together with diet and physical activity, in adults with a BMI of 28 or more, or 24 or more with at least one weight-related condition, and in September 2025 for blood sugar control in adults with type 2 diabetes, according to a published drug review. It was developed by Innovent Biologics together with Eli Lilly, which uses the code LY3305677. A Lilly-funded phase 2 trial in US adults has been published; the published phase 3 trials cited here were all done in China, and the two phase 3 obesity trials were sponsored by Innovent.
Is it worth it for you?
Use this as a quick fit check, not a diagnosis.
Worth considering if…
Probably skip if…
Evidence at a glance
| Goal | Effect | Best fit | Time |
|---|---|---|---|
weight loss in Chinese adults with obesity or overweight Good Evidence | -14.01% on 6 mg vs +0.30% on placebo at 48 weeks (GLORY-1); 15.15 percentage points more than placebo on 9 mg at 60 weeks (GLORY-2) | Chinese adults with obesity, or overweight with a weight-related condition | Measured at 32 to 60 weeks; 32 weeks was the primary time point in GLORY-1 |
blood sugar (HbA1c) in type 2 diabetes Good Evidence | HbA1c 1.43 to 2.02 percentage points lower than placebo (DREAMS-1); 0.24 to 0.30 points lower than dulaglutide (DREAMS-2) | Chinese adults with type 2 diabetes on diet and exercise or oral diabetes medicines | Measured at 24 to 28 weeks |
weight loss in US adults with obesity Limited Evidence | 6.5 to 17.2 percentage points more weight loss than placebo at 32 weeks | US adults with obesity without type 2 diabetes | Measured at 32 weeks, with further loss at 48 weeks |
weight loss in Chinese adults with obesity or overweight
- Effect
- -14.01% on 6 mg vs +0.30% on placebo at 48 weeks (GLORY-1); 15.15 percentage points more than placebo on 9 mg at 60 weeks (GLORY-2)
- Best fit
- Chinese adults with obesity, or overweight with a weight-related condition
- Time
- Measured at 32 to 60 weeks; 32 weeks was the primary time point in GLORY-1
blood sugar (HbA1c) in type 2 diabetes
- Effect
- HbA1c 1.43 to 2.02 percentage points lower than placebo (DREAMS-1); 0.24 to 0.30 points lower than dulaglutide (DREAMS-2)
- Best fit
- Chinese adults with type 2 diabetes on diet and exercise or oral diabetes medicines
- Time
- Measured at 24 to 28 weeks
weight loss in US adults with obesity
- Effect
- 6.5 to 17.2 percentage points more weight loss than placebo at 32 weeks
- Best fit
- US adults with obesity without type 2 diabetes
- Time
- Measured at 32 weeks, with further loss at 48 weeks
Evidence for 3 uses
AI-assisted evidence assessment. Talk to your doctor before relying on any single supplement.
weight loss in Chinese adults with obesity or overweight
Disease adjunctIn GLORY-1, a phase 3 trial in China, 610 adults with a BMI of 28 or more, or 24 to under 28 with a weight-related condition, received mazdutide 4 mg or 6 mg weekly or placebo. At 48 weeks, body weight fell by 11.00% (4 mg) and 14.01% (6 mg), compared with a 0.30% gain on placebo, and 35.7% and 49.5% lost at least 15%, compared with 2.0%. In GLORY-2, 461 Chinese adults with a BMI of 30 or more (average age 33.9, 16.1% with type 2 diabetes) lost 16.65% on 9 mg over 60 weeks, compared with 1.50% on placebo. Both trials were funded by Innovent Biologics, the Chinese developer. They enrolled only Chinese adults and did not test heart outcomes.
Bottom line: Clear weight loss in two Chinese phase 3 trials; results in other populations rest on phase 2 data.
blood sugar (HbA1c) in type 2 diabetes
Biomarker supportIn two phase 3 trials in Chinese adults with type 2 diabetes, mazdutide lowered HbA1c. In DREAMS-1, 320 adults on diet and exercise alone (average HbA1c 8.24%) saw HbA1c fall by 1.57 (4 mg) and 2.15 (6 mg) percentage points at 24 weeks, compared with 0.14 on placebo. In DREAMS-2, 731 adults on oral diabetes medicines had larger HbA1c reductions than with dulaglutide 1.5 mg after 28 weeks (0.24 and 0.30 points more) and lost 3.78% to 5.76% more body weight. Both trials were short and did not measure diabetes complications.
Bottom line: It lowered blood sugar more than placebo and a little more than dulaglutide in short trials.
weight loss in US adults with obesity
Disease adjunctIn a phase 2 trial at 24 US centers, 179 adults with obesity, or overweight with a weight-related condition, and without type 2 diabetes received mazdutide 3 to 6 mg, 10 mg or 16 mg weekly, or placebo, for 48 weeks. At 32 weeks, body weight fell by 7.3%, 15.6% and 18.1%, compared with 0.9% on placebo, with further loss by 48 weeks. Discontinuation because of adverse events was highest on 16 mg (20%). The trial was funded by Eli Lilly, was small and short, and its main result assumed people stayed on treatment.
Bottom line: Higher doses gave more weight loss in US adults in one phase 2 trial, at the cost of more people stopping.
How it works
How to take it
What to track
Bottom line: Approved in China for weight management, unapproved in the US: in the US a registered trial is the only legitimate route.
Safety
Know the common side effects, key cautions, and who should avoid it.
Common side effects
Serious risks
Stopping because of side effects. Adverse events led to stopping treatment in 2.9% on 9 mg vs 0% on placebo in GLORY-2, and in 1.5% (4 mg) and 0.5% (6 mg) vs 1.0% on placebo in GLORY-1. In the US phase 2 trial, 20% stopped on 16 mg, mostly because of stomach side effects.
Class warning, not a finding for mazdutide: approved drugs acting on the GLP-1 receptor carry a boxed warning because they caused thyroid C-cell tumors in rodents, and they are not used in people with a personal or family history of medullary thyroid cancer or MEN 2. GLORY-1 excluded these people.
Class warnings, not findings for mazdutide: the labels of approved GLP-1 medicines warn of pancreatitis, gallbladder disease, dehydration leading to kidney injury, low blood sugar with insulin or a sulfonylurea, severe stomach side effects (not recommended with severe gastroparesis), serious allergic reactions, worsening of diabetic eye disease (retinopathy) in people with type 2 diabetes, a faster heart rate (Wegovy label), and food entering the lungs during anesthesia or deep sedation.
Unknown long-term safety and unknown effects outside China. The published phase 3 trials lasted up to 60 weeks, enrolled only Chinese adults and did not test heart outcomes.
Unapproved products of unknown quality in the US. FDA has warned companies that illegally sold mazdutide falsely labeled "for research purposes" or "not for human consumption" with dosing instructions for people, and says such products are of unknown quality and may be harmful.
Who should avoid it
- Anyone in the US outside a registered clinical trial, because the drug is not FDA-approved and products sold there are unapproved
- People with a personal or family history of medullary thyroid cancer or MEN 2, or with past pancreatitis (excluded from GLORY-1)
- People with moderate to severe depression, severe mental illness or a past suicide attempt (excluded from GLORY-1, so effects in these groups are unknown)
- People who are pregnant, planning a pregnancy or breastfeeding: no human data are published, and labels of approved drugs in the class say they may cause fetal harm
Pregnancy & breastfeeding
Pregnancy: no data on mazdutide in pregnancy are published in the trial reports. As a class warning, the labels of approved GLP-1 weight-loss drugs say they may cause fetal harm; the Wegovy label advises stopping semaglutide at least 2 months before a planned pregnancy. Breastfeeding: no data on mazdutide in breast milk or in breastfed infants are published.
Interactions
Class-based, not a finding for mazdutide: the Wegovy (semaglutide) and Zepbound (tirzepatide) labels say that use with insulin or an insulin secretagogue such as a sulfonylurea may increase the risk of low blood sugar, including severe low blood sugar, and that reducing the dose of the insulin or secretagogue may be necessary. Mazdutide has no FDA label.
Class-based, not a finding for mazdutide: mazdutide acts on the GLP-1 receptor. The Wegovy label says use with other semaglutide-containing products or with any other GLP-1 receptor agonist is not recommended, and the Zepbound label says coadministration with any GLP-1 receptor agonist is not recommended. GLORY-1 excluded people who had used weight-loss drugs in the 3 months before screening.
Class-based, not a finding for mazdutide: the Zepbound label says tirzepatide delays stomach emptying and may affect the absorption of medicines taken by mouth, and says to monitor people taking oral medicines with a narrow therapeutic index (for example warfarin); the Wegovy label says to consider increased clinical or laboratory monitoring with such medicines. A study of mazdutide with warfarin, metformin, atorvastatin and digoxin is listed as completed on ClinicalTrials.gov (NCT05815680), but no results are posted or published.
Choosing a product
What to look for on the label, and what to be skeptical of.
Look for…
Be skeptical of…
Frequently asked questions
Is mazdutide FDA-approved?⌄
No. As of November 19, 2026, it does not appear among FDA's approved drugs, and FDA calls products containing it unapproved drugs. China approved it in June 2025 for long-term weight management in adults and in September 2025 for type 2 diabetes. Only FDA can decide whether it is approved in the US.
Is it legal to buy mazdutide online in the US?⌄
Mazdutide is an unapproved drug in the US. FDA has warned companies that illegally sold it falsely labeled "for research purposes" or "not for human consumption", and it urges people not to buy these products, which are of unknown quality and may be harmful. In the US, a registered clinical trial is the only legitimate way to receive it now.
How does mazdutide compare with semaglutide?⌄
Mazdutide acts on the GLP-1 receptor like semaglutide, plus the glucagon receptor. In Chinese phase 3 trials, average weight loss was 11.00% to 14.01% at 48 weeks on 4 mg or 6 mg, and 16.65% at 60 weeks on 9 mg. DREAMS-3, a Chinese trial comparing mazdutide 6 mg with semaglutide 1 mg in adults with type 2 diabetes and obesity, is listed as completed on ClinicalTrials.gov, but only its design has been published, so comparisons across trials are uncertain.
Why were the main trials only in China?⌄
The published phase 3 trials were sponsored by Innovent Biologics, which develops the drug in China together with Eli Lilly, and China is where it was approved. Eli Lilly has published a phase 2 trial in 179 US adults. Results in Chinese adults may not apply exactly to other populations, which is one reason more trials are needed.
Can I take mazdutide with my supplements or other medicines?⌄
No interaction studies of mazdutide with supplements have been published. Based on the labels of approved GLP-1 medicines, low blood sugar is a risk with insulin or sulfonylureas, the labels say using it with another GLP-1 medicine is not recommended, and slower stomach emptying may affect medicines taken by mouth. Ask a doctor or pharmacist to check your own list.
References by claim
weight loss in Chinese adults with obesity or overweight
weight loss in US adults with obesity
Hsia et al., 2026 · PubMed (2026) link
blood sugar (HbA1c) in type 2 diabetes
Safety
Wegovy (semaglutide) injection and tablets prescribing information · DailyMed (FDA label) link
ClinicalTrials.gov record NCT05607680 (GLORY-1): eligibility criteria · ClinicalTrials.gov link
Zepbound (tirzepatide) prescribing information · DailyMed (FDA label) link
FDA: FDA's concerns with unapproved GLP-1 drugs used for weight loss · FDA link
Interaction: Oral medicines with a narrow safety margin (such as warfarin)
ClinicalTrials.gov record NCT05815680: drug interaction study of IBI362 (mazdutide) with metformin, warfarin, atorvastatin and digoxin · ClinicalTrials.gov link
Track Mazdutide with Pilora
Set up dose reminders, check interactions, and join the community in the Pilora app.
Disclaimer: This page summarizes published clinical-trial data for educational purposes and is not medical advice or a recommendation to use this prescription medication. Dosing, eligibility, and monitoring must be decided by a licensed prescriber.
